-
Piper Jaffray Raises PT On Exellis To $12
Friday, February 18, 2011 - 7:46am | 27Piper Jaffray has raised the price target on Exellis, Inc. (NASDAQ: EXEL) from $9 to $12 and maintains its Overweight rating.
-
Top 4 Mid-Cap Stocks In The Biotechnology Industry With The Highest Operating Margin (TECH, CEPH, ILMN, TLCR)
Friday, February 18, 2011 - 4:08am | 131Below are the top mid-cap biotechnology stocks on the NYSE and the NASDAQ in terms of operating margin. The trailing-twelve-month operating margin at Techne Corporation (NASDAQ: TECH) is 57.32%. TECH's ROE for the same period is 21.58%. The trailing-twelve-month operating margin at Cephalon Inc (...
-
Exelis Announces Cabozantinib Phase 2 Data Demonstrate Encouraging Clinical Activity
Thursday, February 17, 2011 - 5:51pm | 101Exelixis, Inc. (NASDAQ: EXEL) today reported updated interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. The data support the findings that...
-
Deutsche Bank Reiterates Hold On XenoPort (XNPT)
Thursday, February 17, 2011 - 8:16am | 118Deutsche Bank is reiterating its Hold rating and $8 price target on shares of XenoPort (NASDAQ: XNPT). In a note to clients, Deutsche Bank writes, "While XenoPort and partner GSK now have an FDA action date for Horizant and a sound strategy for obtaining final approval, we continue to think that...
-
Luminex and Partners HealthCare Announce Collaboration Agreement
Tuesday, February 15, 2011 - 10:31am | 58Luminex Corporation (Nasdaq: LMNX) announced today that it has teamed with Partners HealthCare toward the discovery of novel biomarkers and development of clinical assays. This program will enable Partners HealthCare Center for Personalized Genetic Medicine (PCPGM) to develop novel molecular...
-
Takeda Enters Into Strategic Partnerships With Covance and Quintiles
Tuesday, February 15, 2011 - 10:07am | 79Takeda Pharmaceuticals International, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, today announced that its Pharmaceutical Development Division has entered into strategic partnerships with Covance (NYSE: CVD) and Quintiles, two of the world's largest full-service...
-
Kendle Promotes Stephen Cutler to President and CEO
Monday, February 14, 2011 - 5:12pm | 88Kendle (Nasdaq: KNDL) today announced that as part of a planned succession Senior Vice President and COO Stephen Cutler, PhD, will become the Company's next President and CEO. Chairman and CEO Candace Kendle, PharmD, will continue to serve as Chairman. Assuming the role of Senior Vice President...
-
President Obama's FY2012 Budget Details Released
Monday, February 14, 2011 - 10:21am | 244Deutsche Bank has published a research report on Healthcare Services & Technology after President Obama released details on his FY2012 budget this morning. In the report, Deutsche Bank writes "The budget is primarily focused on deficit reduction, but the budget for the NIH was actually provided...
-
PerkinElmer Acquires chemagen Biopolymer-Technologie AG
Monday, February 14, 2011 - 9:15am | 69PerkinElmer, Inc. (NYSE: PKI) today announced that it has acquired chemagen Biopolymer-Technologie AG as part of the Company's strategy to advance its offerings to the molecular diagnostics and research markets. chemagen AG, based in Baesweiler, Germany was founded in December 1997. The company's...
-
Citigroup Comments On NIH Budget And F2011 Appropriations (LIFE, ILMN)
Monday, February 14, 2011 - 8:30am | 215Late Friday (2/11), the House Appropriations Committee released details of its budget cuts proposal for the remainder of F2011 (ending 9/30) which will be voted on this week as HR 1, Citigroup reports. “According to the bill, the proposed NIH budget will be cut by $1.6B to $29.3B (-5%) vs. F2010...
-
Puts Purchased on Exelixis, Inc. (EXEL)
Friday, February 11, 2011 - 1:04pm | 129Shares of Exelixis, Inc. (NASDAQ: EXEL) are higher on the session by 1.86%, currently trading at $9.85. The stock has been moving largely higher over the past six months and is currently trading above the 50-day and 200-day moving averages. Options traders are buying puts on the name today. A...
-
Bruker Corporation to Release Q4 Financial Results on February 23rd, 2011
Friday, February 11, 2011 - 11:42am | 50Bruker Corporation (NASDAQ: BRKR) announced today that it plans to release its fourth quarter and fiscal year 2010 financial results on Wednesday, February 23rd, 2011 before the market opens. Bruker will then host an operator-assisted earnings conference call that morning at 9:00 AM Eastern Time.
-
Caliper Life Sciences' To Release Fourth Quarter and Fiscal Year 2010
Friday, February 11, 2011 - 9:15am | 68Caliper Life Sciences, Inc. (Nasdaq: CALP) will conduct a conference call discussing the company's fourth quarter and fiscal year 2010 financial results at 5:00 pm Eastern (2:00 pm Pacific) on Wednesday, February 23, 2011. Kevin Hrusovsky, President and Chief Executive Officer and Peter McAree,...
-
SeraCare Reports Q1 EPS of $0.08
Friday, February 11, 2011 - 8:42am | 57SeraCare Life Sciences Inc (NASDAQ: SRLS) reports its Q1 EPS at $0.08, versus the consensus of $0.08. SRLS reports its Q1 revenue at $10.5 million, versus the consensus of $11.83 million. SRLS shares gained 2.07% to close at $4.44 yesterday. Read more from Benzinga's Company news.
-
SeraCare Reports First Quarter Fiscal Year 2011 Results
Friday, February 11, 2011 - 8:33am | 63SeraCare Life Services (NASDAQ: SRLS) earned net income of $1.6 million, which included a non-recurring reorganization benefit of $0.8 million, and earnings per share on a basic and diluted basis of $0.08 for the quarter ended December 31, 2010 SeraCare reported revenue of $10.5 million for the...